Quality of life in patients with advanced colorectal cancer: What has been learnt?

European Journal of Cancer

Volumn 39, Issue 3, 2003, Pages 287-294

  Conroy, T ^a   Bleiberg, H ^b   Glimelius, B ^c  

^a CENTRE ALEXIS VAUTRIN   (France)

^b JULES BORDET INSTITUTE   (Belgium)

^c University Hospital   (Sweden)

Author keywords

Chemotherapy; Colorectal cancer; Quality of life

Indexed keywords

ACCURACY; ADVANCED CANCER; ANALYTIC METHOD; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; HUMAN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

EID: 0037304896     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00664-0     Document Type: Article

References (57)

1. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J. Clin. Oncol. 14:1996;671-679.
2. Palliative chemotherapy for advanced colorectal cancer. systematic review and meta-analysis Br. Med. J. 321:2000;531-536.
3. Spitzer W.O., Dobson A.J., Hall J.et al. Measuring the quality of life cancer patients. A concise QL-index for use by physicians. J. Chron. Dis. 34:1981;585-597.
4. Sloan J.A., Loprinzi C.L., Kuross S.A.et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J. Clin. Oncol. 16:1998;3662-3673.
5. Schipper H., Clinch J., McMurray A., Lewitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J. Clin. Oncol. 2:1984;472-483.
6. Aaronson N.K., Ahmedzai S., Bergman B.et al. The European Organization for Research and Treatment of Cancer QLQ-C30. a Quality-of-Life instrument for use in international clinical trials in oncology J. Natl. Cancer Inst. 85:1993;365-376.
7. Seymour M.T., Tabah-Fisch I., Homerin M. Quality of Life (HRQoL) in advanced colorectal cancer (ACC). a comparison of HRQoL during bolus plus infusion 5FU/Leucovorin (LV5FU2) with or without oxaliplatin Proc. Am. Soc. Clin. Oncol. 18:1999;234a.
8. Osoba D., Rodrigues G., Myles J., Zee B., Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16:1998;139-144.
9. Cella D.F., Tulsky D.S., Gray G.et al. The Functional Assessment of Cancer Therapy scale. development and validation of the general measure J. Clin. Oncol. 11:1993;570-579.
10. Cella D., Hahn E.A., Dineen K. Meaningful change in cancer-specific quality of life scores. differences between improvement and worsening Qual. Life Res. 11:2002;207-221.
11. Conroy T., Mercier M., Bonneterre J.et al. Comparison of quality of life cancer-specific instruments. FACT-G, EORTC QLQ-C30 and FLIC Proc. Am. Soc. Clin. Oncol. 20:2001;401a.
12. De Haes J.C.J.M., Van Knippenberg F.C.E., Neijt J.P. Measuring psychological and physical distress in cancer patients. structure and application of the Rotterdam Symptom Checklist Br. J. Cancer. 62:1990;1034-1038.
13. Zigmund A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 67:1983;361-370.
14. Bosset J.F., Schraub S., Pelissier E.et al. Proposition of a specific quality of life scale for patients treated by conservative surgery for rectal cancer. Lyon Chir. 89:1993;135.
15. Sprangers M.A.G., te Velde A., Aaronson N.K. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur. J. Cancer. 35:1999;238-247.
16. Ward W.L., Hahn E.A., Mo F., Hernandez L., Tulsky D.S., Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual. Life Res. 8:1999;181-195.
17. Smyth J.F., Hardcastle J.D., Denton G.et al. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann. Oncol. 6:1995;948-949.
18. Sullivan B.A., McKinnis R., Laufman L. Quality of life in patients with metastatic colorectal cancer receiving chemotherapy. a randomized, double-blind trial comparing 5-FU versus 5-FU with leucovorin Pharmacotherapy. 15:1995;600-607.
19. Schöffski P., Schellenberger U., Köhne C.H.et al. Quality of life predicts for both response and survival in patients treated for metastatic colorectal cancer. Results of a randomized phase III study. Proc. Am. Soc. Clin. Oncol. 5:1996;213.
20. Earlam S., Glover C., Fordy C., Burke D., Allen-Mersch T.G. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J. Clin. Oncol. 14:1996;171-175.
21. Hilgenfeld R.U., Mansmann U., Guggenmoos-Holzmann I., Thiel E., Kreuser E.D. Quality of life (QL) is a prognostic factor (PF) for survival in patients with advanced colorectal cancer (CRC). Eur. J. Cancer. 33(Suppl. 8):1997;S170.
22. Mormont M.C., Waterhouse J., Bleuzen P.et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin. Cancer Res. 6:2000;3038-3045.
23. Maughan T.S., James R.D., Kerr D.J.et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer. a multicentre randomised trial Lancet. 359:2002;1555-1563.
24. Maisey N.R., Norman A., Watson M., Allen M.J., Hill M.E., Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur. J. Cancer. 38:2002;1351-1357.
25. Glimelius B., Graf W., Hoffman K., Pahlman L., Sjödén P.O., Wennberg A. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. Acta Oncol. 31:1992;645-651.
26. Homsi J., Walsh D., Nelson K.A.et al. Symptom assessment in advanced cancer. patient report versus systematic assessment Proc. Am. Soc. Clin. Oncol. 20:2001;386a.
27. Glimelius B., Hoffman K., Graf W., Pahlman L., Sjöden P.E. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer. 73:1994;556-562.
28. Cunningham D., Zalcberg J.R., Rath U.et al. Final results of a randomised trial comparing "Tomudex"® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol. 7:1996;961-965.
29. Scheithauer W., Rosen H., Kornek G.-V., Sebesta C., Depisch D. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 306:1993;752-755.
30. Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 344:1994;1255-1260.
31. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. a randomized trial J. Clin. Oncol. 10:1992;904-911.
32. Ackland S.P., Moore M., Jones M.et al. A meta-analysis of two randomized trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;132a.
33. Seymour M.T., Slevin M.L., Kerr D.J.et al. Randomized trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J. Clin. Oncol. 14:1996;2280-2288.
34. Glimelius B., Hoffman K., Olafsdottir M., Pahlman L., Sjöden P.O., Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma. a randomized comparison of two regimens Eur. J. Cancer Clin. Oncol. 25:1989;829-835.
35. De Gramont A., Figer A., Seymour M.et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2000;2938-2947.
36. Schöffski P., Köhne C.H., Schellenberger U.et al. Does effective chemotherapy metastatic colorectal cancer (CC) improve quality of life (QL). Preliminary results of a randomized phase II-study using the EORTC QLQ C30. Eur. J. Cancer. 31A:1995;S62.
37. Ross P., Norman A., Cunningham D.et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann. Oncol. 8:1997;995-1001.
38. Douillard J.Y., Cunningham D., Roth A.D.et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. a multicenter randomised trial Lancet. 355:2000;1041-1047.
39. Saltz L.B., Cox J.V., Blanke C.et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343:2000;905-914.
40. Moinpour C.M., Sawyers Triplett J., McKnight B.et al. Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology. 9:2000;340-354.
41. Bernhard J., Hurny C., Maibach R., Herrmann R., Laffer U. Quality of life as subjective experience. reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy Ann. Oncol. 10:1999;775-782.
42. Maughan T., James R., Kerr D.et al. Continuous vs intermittant chemotherapy for advanced colorectal cancer. preliminary results of the MRC Cr06b randomised trial Proc. Am. Soc. Clin. Oncol. 20:2001;125a.
43. Loprinzi C.L., Kuross S.A., O'Fallon J.R.et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J. Clin. Oncol. 12:1994;1121-1125.
44. Cunningham D., Pyrhönen S., James R.D.et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
45. Rougier P., Van Cutsem E., Bajetta E.et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
46. Henry-Launois B., Becouarn Y., Aussage P. Bénéfices cliniques de la stabilisation tumorale lors d'une chimiothérapie de deuxième ligne dans le cancer colorectal métastatique. Bull. Cancer. 86:1999;195-201.
47. McLachlan S.A., Allenby A., Matthews J.et al. Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. J. Clin. Oncol. 19:2001;4117-4125.
48. Empereur F., Désandes E., Guillemin F., Léonard I., Klein S., Briançon S. Measuring quality of life in clinical practice improved patient satisfaction. Qual. Life Res. 10:2001;195.
49. Velikova G., Wright E.P., Smith A.B.et al. Automated collection of quality of life data. a comparison of paper and computer touch-screen questionnaires J. Clin. Oncol. 17:1999;998-1007.
50. Moinpour C.M., Lovato L.C. Ensuring the quality of quality of life data. the Southwest oncology group experience Stat. Med. 17:1998;641-651.
51. Kaasa S., Hjermstad M.J., Jordhoy M.S., Wisloff F., Loge J.H. Compliance in quality of life data. a Norwegian experience Stat. Med. 17:1998;623-632.
52. Bernhard J., Gusset H., Hurny C. Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research. Stat. Med. 17:1998;633-639.
53. Young T, De Haes H, Curran D, et al. EORTC Guidelines for Assessing Quality of Life in EORTC Clinical Trials. The EORTC Quality of Life Group and EORTC Quality of Life Unit, Version 2, March 2002.
54. Bernhard J, Gelber RD, eds. Workshop on missing data in quality of life research in cancer trials: practical and methodological issues. Stat. Med. 1998, 17, 511-796.
55. Moynihan C. Patient 'non-compliance' and 'missing data' in quality of life research. where does the problem lie? Eur. J. Cancer. 34:1998;9-11.
56. Cocconi G., Cunningham D., Van Cutsem E.et al. Open, randomised, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Oncol. 16:1998;2943-2952.
57. Nordin K., Steel J., Hoffman K., Glimelius B. Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. Br. J. Cancer. 85:2001;1265-1272.